IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $2.11B
• Dividend Yield: N/A
• Average Volume (3M): 1.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: -41.48%
• EPS Growth: -73.55%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 87,643,684
• 10 Day Avg. Volume: 901,693
• 30 Day Avg. Volume: 1,004,854
• PEG Ratio: -0.11
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 299.87
• P/FCF Ratio: -8.35
• Enterprise Value/Market Cap: 0.58
• Enterprise Value/Revenue: 173.79
• Enterprise Value/Gross Profit: 231.28
• Enterprise Value/Ebitda: -3.40
• 1Y Price Target: $40.22
• Price Target Upside: 63.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 56 Neutral
• Price Target: $26.00 ▲(5.56% Upside)

IDEAYA Biosciences has a moderate overall score primarily driven by strong technical momentum despite significant financial challenges. The lack of profitability and negative cash flows weigh heavily on the valuation, but positive market trends provide a short-term boost.

Positive Factors

Clinical Trials

All programs are on track, with the next major catalyst being median progression-free survival for the Phase 3 trial of darovasertib + crizotinib in metastatic uveal melanoma.

Financial Outlook

The revised price target still implies a 73% upside potential relative to current levels.

Pipeline Progress

Analyst remains enthusiastic about Ideaya Biosciences' pipeline and scientific approach.

Negative Factors

Licensing Concerns

Investors have previously criticized IDYA's licensing deal for IDE849, noting that it had committed considerable near-term capital for an asset in an increasingly crowded SCLC landscape.

Market Competition

IDYA is moving daro + criz into HLA-A*02:01 negative patients first as the unmet need is greater with Kimmtrak approved in positives, and this population makes up at least ~66% of patients.

Price Target

Price target moves 22% lower due to model updates and assumptions.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

How the Company Makes Money

IDEAYA Biosciences generates revenue through a combination of its own product development efforts and strategic partnerships. The company primarily earns money by advancing its pipeline of drug candidates through various stages of clinical trials, leading to potential commercialization. Additionally, IDEAYA enters into collaborations and licensing agreements with larger pharmaceutical companies, which can provide upfront payments, milestone payments based on development progress, and royalties on future sales. These partnerships not only offer financial support but also access to resources and expertise necessary for efficient drug development. The company may also receive funding through grants and investments to support its research initiatives.

IDEAYA Biosciences Financial Statement Overview

Summary

IDEAYA Biosciences is experiencing financial difficulties with declining revenues and consistent net losses. Although it has a strong equity position, the lack of profitability and negative cash flows are significant risks.

Income Statement

The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.

Balance Sheet

IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.00M	7.00M	23.39M	50.93M	27.94M	19.54M
Gross Profit	5.26M	7.00M	19.38M	48.83M	26.22M	-20.16M
EBITDA	-357.95M	-326.98M	-130.42M	-60.40M	-48.54M	-33.96M
Net Income	-306.31M	-274.48M	-112.96M	-54.81M	-47.53M	-32.27M
Balance Sheet
Total Assets	1.10B	1.12B	649.32M	387.97M	381.35M	298.27M
Cash, Cash Equivalents and Short-Term Investments	692.51M	676.32M	525.11M	373.15M	368.06M	283.58M
Total Debt	25.97M	19.17M	2.87M	3.48M	5.18M	6.72M
Total Liabilities	76.51M	64.94M	28.23M	387.97M	381.35M	298.27M
Stockholders Equity	1.02B	1.06B	621.09M	349.45M	301.51M	198.27M
Cash Flow
Free Cash Flow	-267.98M	-251.44M	-117.59M	-90.62M	-58.42M	54.97M
Operating Cash Flow	-264.11M	-247.58M	-115.22M	-87.17M	-55.78M	55.46M
Investing Cash Flow	-68.77M	-502.56M	-158.46M	-33.40M	-69.67M	-146.24M
Financing Cash Flow	354.58M	677.55M	362.72M	97.17M	145.45M	128.75M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 24.63 is above the 20-day moving average (MA) of 24.19, above the 50-day MA of 22.92, and above the 200-day MA of 22.24, indicating a bullish trend. The MACD of 0.43 indicates Positive momentum. The RSI at 57.20 is Neutral, neither overbought nor oversold. The STOCH value of 73.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥352.94B	11.56	-1.45%	2.37%	9.60%	-12.34%
IMCR	63 Neutral	$1.63B	―	-5.38%	―	26.90%	62.72%
IDYA	56 Neutral	$2.11B	―	-35.09%	―	-41.48%	-73.55%
KYMR	53 Neutral	$3.04B	―	-33.26%	―	-49.51%	-44.09%
CGON	46 Neutral	$1.95B	―	-20.95%	―	―	―
ETNB	42 Neutral	$1.33B	―	-86.86%	―	―	-82.75%
BEAM	41 Neutral	$1.65B	―	-41.94%	―	-82.90%	-155.64%

IDEAYA Biosciences Corporate Events

IDEAYA Biosciences Appoints New Chief Financial Officer

On June 26, 2025, IDEAYA Biosciences appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer. This strategic appointment may influence the company’s financial management and operational strategies.

The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

IDEAYA Biosciences Holds Annual Stockholders Meeting

On June 24, 2025, IDEAYA Biosciences held its Annual Meeting of Stockholders where three proposals were voted on. The election of two Class III directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation were addressed. The election saw Jeffrey L. Stein, Ph.D., and Scott W. Morrison nominated, with Stein receiving more votes. The ratification of the auditor was largely uncontested, and the executive compensation received a majority vote in favor, indicating shareholder support for the company’s leadership and financial oversight.

The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.